GLP-1 News — Week of October 26, 2026
The GLP-1 stories that mattered this week — what happened, and what each one means for you if you're using or considering these medications. Every story links to its primary source, and nothing here is influenced by advertisers.
Eli Lilly’s Q3 2026 results show GLP-1 demand powering record revenue
Eli Lilly reported third quarter 2026 revenue of 24.4 billion dollars, up 39 percent year over year, driven mainly by Mounjaro for type 2 diabetes and Zepbound for obesity. The company raised full-year 2026 revenue guidance to 91–92 billion dollars, signaling that demand for its injectable GLP-1–based drugs remains exceptionally strong. (2026-10-29)
What this means for you: High and rising demand makes it more likely that Lilly will keep investing in manufacturing and new GLP-1 drugs, which could help long-term availability. In the near term, though, you should still expect tight supply in some places, strict insurance rules, and high list prices, so planning ahead for refills and coverage remains important.
Source: Eli Lilly
Related on Metabolic Ledger: /cost/zepbound-cost
Lilly’s GLP-1 revenue strength eases investor worries about U.S. price pressure
Reuters’ coverage of Lilly’s Q3 2026 results highlighted that booming sales of Zepbound and related injections led the company to raise revenue forecasts. The report noted that Lilly’s reduced profit guidance was tied to deal-related research and development charges rather than to any visible pressure from U.S. government health plans such as Medicare and Medicaid on GLP-1 pricing. (2026-10-29)
What this means for you: For now, you should not expect big, policy-driven price cuts on Lilly’s GLP-1 drugs, and list prices are likely to stay high. If you rely on Medicare or Medicaid, you will still need to plan around strict coverage criteria, prior authorization hurdles, and potentially large out-of-pocket costs unless you clearly meet your plan’s rules.
Source: Reuters
Related on Metabolic Ledger: /cost/medicare-glp1-coverage
FDA reiterates tight limits on compounded GLP-1s and warns about unapproved online products
The U.S. Food and Drug Administration has clarified that compounders can only make GLP-1 copies under narrow conditions and that semaglutide and tirzepatide are not on the agency’s 503B clinical-need bulks list or on the current shortages list. In updated communications, FDA also warns about unapproved GLP-1 products sold online, citing risks from foreign active ingredients, poor storage, and quality problems. (2026-04-01)
What this means for you: If you are being offered cheap compounded semaglutide or tirzepatide, especially online, you should assume tighter enforcement and higher safety risk unless you have carefully verified that the pharmacy is state-licensed and operating within FDA rules. For many people, this will mean shifting away from compounded workarounds and focusing on brand-name access paths, including savings cards and support programs, if you and your clinician decide a GLP-1 is appropriate.
Source: FDA
Related on Metabolic Ledger: /regulatory/fda-compounding-cliff
Novo Nordisk’s patient assistance program remains a key but narrow safety net
Novo Nordisk continues to run a Patient Assistance Program through NovoCare that provides certain Novo medicines at no cost to eligible U.S. patients who are citizens or legal residents, have Medicare or no insurance, and meet strict income criteria. Approved patients can receive medications by shipment from a specialty pharmacy. (2026-10-30)
What this means for you: If you use a Novo drug and have Medicare or no insurance and very limited income, this program may reduce your costs dramatically and could be worth exploring with your clinician or pharmacist. If you have commercial insurance or earn above the income thresholds, this program likely will not apply, and you will need to focus on other cost strategies such as savings cards, appeals, or switching to different GLP-1 options.
Source: Novo Nordisk
Related on Metabolic Ledger: /cost/cheapest-place-to-get-wegovy